Advent Life Sciences
No summary available yet.
Advent Life Sciences is the real deal - a proper company builder that actually gets drugs approved, not just another PowerPoint VC. Since the year 2006, Advent-backed companies have brought fifteen innovative medicines and products to approval with our initial investment often being as early as Seed stage or Series A. Their crown jewel was KaNDy Therapeutics, which they spun out and sold to Bayer for $875 million - that's the kind of outcome that gets LPs' attention. The partners have genuine biotech operational experience, not just finance backgrounds, and they're hands-on without being micromanaging. They're particularly strong at company formation and early-stage value creation. The team is lean but experienced, with good transatlantic reach through their Boston presence. However, their portfolio is quite concentrated in traditional biopharma plays - if you're doing digital health or medical devices, this might not be your first call.
- —Best for: Early-stage biotech founders who want hands-on, experienced partners
- —Known for: Company building and getting drugs to market approval
- —Sweet spot: First-in-class drug discovery, Series A investments £6-7M
We start and invest in early and mid-stage companies with a first-in-class or best-in-class approach. Our investments are focussed in new drug discovery - small molecules, biologics and new modalities - med tech, enabling technologies and vaccines. The firm seeks to back truly innovative companies that have a first-in-class or best-in-class approach and who are looking for a well-connected partner on the road to success.
It primarily invests in Series A round in United Kingdom based startups. The firm seeks to invest in life sciences businesses focusing on new drug discovery, small molecules, biologics, and new modalities, med tech, enabling technologies, and vaccines industries. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications.
General Partner at Advent, co-manager of their first life sciences fund with Raj Parekh. He and his fellow General Partner Raj Parekh set out to change this attitude when they joined Advent in the middle of the decade. As part of the financing, Shahzad Malik, MD, General Partner at Advent Life Sciences. Known for hands-on entrepreneurial approach and backing high-potential life sciences companies.
General Partner and co-manager of the first life sciences fund with Shahzad Malik. I have collaborated with Raj Parekh for over 20 years, and I have a high regard for what he and Shahzad Malik have accomplished at Advent. Long-standing track record in European life sciences venture capital with decades of investment experience.
General Partner at Advent Life Sciences. "Cyted has demonstrated a rare combination of clinical innovation, patient-centered delivery, and commercial execution with an impressive foundation in the UK. We're proud to support its next phase of growth," said Kaasim Mahmood, General Partner at Advent Life Sciences.
Based in the UK, appointed General Partner. Dominic previously spent eight years as a Partner in the investment team of Syncona, where he was involved in the founding, funding, and building of several life science businesses. "Advent is one Europe's leading venture capital firms in the life sciences space with a long successful track record resulting in an impressive 14 approved medicines and products to the benefit of patients."
Based in Boston, USA, joins as Venture Partner. "I'm delighted to join the Advent team and provide on-the-ground in-market support in Boston, USA, right at the heart of the world's biggest cluster of biotech expertise." Provides US market presence and biotech expertise from Boston.
Have a specific question about Advent Life Sciences?
Ask Bernie →